Literature DB >> 8828419

Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat.

G S Rose1, L M Tocco, G A Granger, P J DiSaia, T C Hamilton, A D Santin, J C Hiserodt.   

Abstract

OBJECTIVE: Our purpose was to develop and characterize a spontaneously arising, nonimmunogenic experimental animal model of epithelial ovarian cancer. STUDY
DESIGN: NuTu-19 is a cell line derived from a poorly differentiated adenocarcinoma formed in a female athymic mouse after subcutaneous injection of spontaneously transformed Fischer 344 rat ovarian surface epithelial cells. This cell line was injected intraperitoneally into naive, immunocompetent Fischer 344 rats to determine tumor growth and animal survival. Immunogenicity of this cell line was determined by repetitive vaccination of naive rats with either mitomycin C-treated or irradiated (5000 cGy) NuTu-19 cells, followed by intraperitoneal rechallenge with viable tumor cells. Kaplan-Meier survival analysis was used to analyze survival data. Major histocompatibility complex class I and class II and intercellular adhesion molecule-1 cell surface antigens were determined by fluorescence-activated cell sorting analysis.
RESULTS: NuTu-19 cells injected intraperitoneally grew progressively as numerous serosal nodules (peritoneum, omentum, diaphragm, liver, bowel), exhibited local tissue invasion and formed malignant ascites in a manner typical for human ovarian epithelial carcinomas. Animal survival was dosage dependent where as few as 10(4) cells were fatal when introduced intraperitoneally; mean animal survival was noted to be approximately 49 days when 10(5) cells were injected intraperitoneally. Repetitive immunizations of animals with large doses (10(7)) of inactivated NuTu-19 cells did not confer immunity to the animals, which all died on subsequent challenge with viable parental tumor cells. NuTu-19 cells expressed high levels of major histocompatibility complex class I and intercellular adhesion molecule-1 cell surface antigens and very low levels of major histocompatibility complex class II antigens.
CONCLUSION: This is the first report of a reliable, spontaneously arising, nonimmunogenic epithelial ovarian cancer animal model. Because this model exists in an immunocompetent animal, it will be useful for studying the biologic and immunologic features of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8828419     DOI: 10.1053/ob.1996.v175.a73595

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  12 in total

1.  Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells.

Authors:  Kyu Kwang Kim; Thilo S Lange; Rakesh K Singh; Laurent Brard
Journal:  BMC Cancer       Date:  2010-02-25       Impact factor: 4.430

2.  Xenograft and Transgenic Mouse Models of Epithelial Ovarian Cancer and Non Invasive Imaging Modalities to Monitor Ovarian Tumor Growth In situ -Applications in Evaluating Novel Therapeutic Agents.

Authors:  Denise C Connolly; Harvey H Hensley
Journal:  Curr Protoc Pharmacol       Date:  2009-06-01

3.  Identification and characterization of a spontaneous ovarian carcinoma in Lewis rats.

Authors:  Allison C Sharrow; Brigitte M Ronnett; Christopher J Thoburn; James P Barber; Robert L Giuntoli; Deborah K Armstrong; Richard J Jones; Allan D Hess
Journal:  J Ovarian Res       Date:  2010-03-31       Impact factor: 4.234

4.  Efficacy of a non-hypercalcemic vitamin-D2 derived anti-cancer agent (MT19c) and inhibition of fatty acid synthesis in an ovarian cancer xenograft model.

Authors:  Richard G Moore; Thilo S Lange; Katina Robinson; Kyu K Kim; Alper Uzun; Timothy C Horan; Nada Kawar; Naohiro Yano; Sharon R Chu; Quanfu Mao; Laurent Brard; Monique E DePaepe; James F Padbury; Leggy A Arnold; Alexander Brodsky; Tun-Li Shen; Rakesh K Singh
Journal:  PLoS One       Date:  2012-04-03       Impact factor: 3.240

5.  Minimally-invasive debulking of ovarian cancer in the rat pelvis by means of photodynamic therapy using the pegylated photosensitizer PEG-m-THPC.

Authors:  R Hornung; M K Fehr; J Monti-Frayne; B J Tromberg; M W Berns; Y Tadir
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

6.  A new spontaneously transformed syngeneic model of high-grade serous ovarian cancer with a tumor-initiating cell population.

Authors:  Curtis W McCloskey; Reuben L Goldberg; Lauren E Carter; Lisa F Gamwell; Ensaf M Al-Hujaily; Olga Collins; Elizabeth A Macdonald; Kenneth Garson; Manijeh Daneshmand; Euridice Carmona; Barbara C Vanderhyden
Journal:  Front Oncol       Date:  2014-03-18       Impact factor: 6.244

7.  Apoptotic and chemotherapeutic properties of iron (III)-salophene in an ovarian cancer animal model.

Authors:  Thilo S Lange; Carolyn McCourt; Rakesh K Singh; Kyu Kwang Kim; Ajay P Singh; Brian S Luisi; Onur Alptürk; Robert M Strongin; Laurent Brard
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

8.  In vivo bioluminescence imaging of locally disseminated colon carcinoma in rats.

Authors:  S Zeamari; G Rumping; B Floot; S Lyons; F A Stewart
Journal:  Br J Cancer       Date:  2004-03-22       Impact factor: 7.640

9.  Photodynamic diagnosis of ovarian cancer using hexaminolaevulinate: a preclinical study.

Authors:  F Lüdicke; T Gabrecht; N Lange; G Wagnières; H Van Den Bergh; L Berclaz; A L Major
Journal:  Br J Cancer       Date:  2003-06-02       Impact factor: 7.640

10.  Modeling High-Grade Serous Carcinoma: How Converging Insights into Pathogenesis and Genetics are Driving Better Experimental Platforms.

Authors:  Paul Michael Jones; Ronny Drapkin
Journal:  Front Oncol       Date:  2013-08-26       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.